13F filer · CIK 1553936
TYBOURNE CAPITAL MANAGEMENT (HK) LTD
HONG KONG, K3 · filing since Q2 2013 · last filing Nov 6, 2025
Reported value
$30.9M
$-3.6M vs prior
Positions
4
New / sold out
0 / 2
Added / reduced
0 / 2
Turnover
0.0%
buys $0 · sells $11.1M
Top-10 weight
100.0%
Biggest buys vs Q2 2025
No new or increased positions this quarter.
Biggest sells vs Q2 2025
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Sold out | BICYCLE THERAPEUTICS LTD-ADR (BCYC US) | -993,743 | -100.0% | $-6.9M |
| Sold out | MALIBU BOATS INC (MBUU US) | -66,705 | -100.0% | $-2.1M |
| Reduced | TAYSHA GENE THERAPIES INC (TSHA US) | -395,000 | -9.6% | $-1.3M |
| Reduced | ZENTALIS PHARMACEUTICALS INC (ZNTL US) | -516,666 | -35.0% | $-780.2K |
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q3 2025
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | TAYSHA GENE THERAPIES INC (TSHA US)COM SHS | 3,700,000 | $12.1M | 39.11% |
| 2 | FORTE BIOSCIENCES INC (FBRX US)COM NEW | 786,647 | $11.8M | 38.15% |
| 3 | ALUMIS INC (ALMS US)COM | 1,399,250 | $5.6M | 18.05% |
| 4 | ZENTALIS PHARMACEUTICALS INC (ZNTL US)COM | 961,486 | $1.5M | 4.69% |